Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-Lipolytic Strategy for HIV Lipodystrophy

NCT00246402 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00246402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-Lipolytic Strategy for HIV Lipodystrophy
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2002
Completion date
August 31, 2006
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases, heart diseases, hiv infections, hyperlipidemia, hypertriglyceridemia, insulin resistance